Alfuzosin

Alfuzosin
Clinical data
Pronunciation	/ælˈfjuːzoʊsɪn/ al-FEW-zoh-sin
Trade names	Uroxatral, others
AHFS/Drugs.com	Monograph
MedlinePlus	a64002
License data	US DailyMed: Alfuzosin;
Pregnancy; category	AU: B2; ;
Routes of; administration	By mouth
Drug class	α1 blocker
ATC code	G04CA01 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	49%
Protein binding	82–90%
Metabolism	Liver (CYP3A4-mediated)
Elimination half-life	10 hours
Excretion	Feces (69%) and Urine (24%)
Identifiers
	IUPAC name (RS)-N-[3-[(4-Amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide;
CAS Number	81403-80-7 ;
PubChem CID	2092;
IUPHAR/BPS	7109;
DrugBank	DB00346 ;
ChemSpider	2008 ;
UNII	90347YTW5F;
KEGG	D07124 ;
ChEBI	CHEBI:51141 ;
ChEMBL	ChEMBL709 ;
CompTox Dashboard (EPA)	DTXSID6048549 ;
ECHA InfoCard	100.108.671
Chemical and physical data
Formula	C19H27N5O4
Molar mass	389.456 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NCCCN(c2nc1cc(OC)c(OC)cc1c(n2)N)C)C3OCCC3;
	InChI InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23) ; Key:WNMJYKCGWZFFKR-UHFFFAOYSA-N ;
	(verify)

Alfuzosin, sold under the brand name Uroxatral among others, is a medication of the α₁ blocker class. It is used to treat benign prostatic hyperplasia (BPH).

As an antagonist of the α₁-adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making urination easier.